APTO vs. PMCB, AIM, EVAX, ZIVO, NSTGQ, SNTI, PLUR, COEP, WINT, and IKT
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include PharmaCyte Biotech (PMCB), AIM ImmunoTech (AIM), Evaxion Biotech A/S (EVAX), ZIVO Bioscience (ZIVO), NanoString Technologies (NSTGQ), Senti Biosciences (SNTI), Pluri (PLUR), Coeptis Therapeutics (COEP), Windtree Therapeutics (WINT), and Inhibikase Therapeutics (IKT). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences (NASDAQ:APTO) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 9.5% of Aptose Biosciences shares are held by insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aptose Biosciences presently has a consensus price target of $19.80, indicating a potential upside of 1,550.00%. Given Aptose Biosciences' higher possible upside, equities analysts clearly believe Aptose Biosciences is more favorable than PharmaCyte Biotech.
In the previous week, PharmaCyte Biotech had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for PharmaCyte Biotech and 0 mentions for Aptose Biosciences. PharmaCyte Biotech's average media sentiment score of 1.00 beat Aptose Biosciences' score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the news media.
PharmaCyte Biotech's return on equity of -9.69% beat Aptose Biosciences' return on equity.
PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences received 375 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
Aptose Biosciences has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
Summary
PharmaCyte Biotech beats Aptose Biosciences on 7 of the 13 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
